Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study

NCT06651203 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT06651203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06651203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Not yet recruiting
Start date
November 1, 2024
Completion date
November 1, 2029
Enrollment
460 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t cell lymphoma, mycosis fungoides/sezary syndrome